Liraglutide Suppresses Obesity and Hyperglycemia Associated with Increases in Hepatic Fibroblast Growth Factor 21 Production in KKA^y Mice

Figure 3

The effects of intraperitoneal injection of liraglutide (150 μg/kg) or saline over 3 days on (a) daily food intake, (b) body weight changes, (c) blood glucose levels, and (d) plasma active GLP-1 levels in individually housed KKA^y mice. Open bar; saline controls and filled bar; liraglutide treatment. Basal body weight in 6-week-old KKA^y mice treated with or without liraglutide was 31.2±0.6 g and 32.2±0.5 g, respectively. Data are presented as the mean values ± SEM (𝑛=6 for each group of animals). ^∗𝑃<0.05.

(a)

(b)

(c)

(d)